Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

Autio, K. A., Antonarakis, E. S., Mayer, T. M., Shevrin, D. H., Stein, M. N., Vaishampayan, U. N., Morris, M. J., Slovin, S. F., Heath, E. I., Tagawa, S. T., Rathkopf, D. E., Milowsky, M. I., Harrison, M. R., Beer, T. M., Balar, A. V., Armstrong, A. J., George, D. J., Paller, C. J., Apollo, A., … Scher, H. I. (2021). Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. European Urology Open Science, 34, 70–78. https://doi.org/10.1016/j.euros.2021.09.015
Authors:
Karen A. Autio
Emmanuel S. Antonarakis
Tina M. Mayer
Daniel H. Shevrin
Mark N. Stein
Ulka N. Vaishampayan
Michael J. Morris
Susan F. Slovin
Elisabeth I. Heath
Scott T. Tagawa
Dana E. Rathkopf
Matthew I. Milowsky
Michael R. Harrison
Tomasz M. Beer
Arjun V. Balar
Andrew J. Armstrong
Daniel J. George
Channing J. Paller
Arlyn Apollo
Daniel C. Danila
Julie N. Graff
Luke Nordquist
Erica S. Dayan Cohn
Kin Tse
Nicole A. Schreiber
Glenn Heller
Howard I. Scher
Affiliated Authors:
Mark N. Stein
Author Keywords:
abiraterone
androgen deprivation therapy
androgen
biochemical recurrence
degarelix
prostate cancer
prostate-specific antigen
Publication Type:
Article
Unique ID:
10.1016/j.euros.2021.09.015
Publication Date:
Data Source:
Scopus

Record Created: